Tofasig contains Tofacitinib, an oral medication used to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It belongs to a class of drugs called Janus kinase (JAK) inhibitors and works by reducing the overactive immune response that causes inflammation and tissue damage.

Mechanism of action:
Tofacitinib blocks JAK enzymes, which are involved in signaling pathways that activate immune cells. By inhibiting these enzymes, Tofasig reduces inflammation, joint pain, swelling, and tissue damage caused by autoimmune diseases.

Uses:

• Rheumatoid arthritis in adults who have not responded well to conventional therapy

• Psoriatic arthritis

• Ulcerative colitis in adults

• Helps reduce pain, swelling, stiffness, and improve physical function

Adverse effects:
Common side effects include upper respiratory infections, headache, diarrhea, nausea, and increased cholesterol levels. Serious but less common effects include serious infections (like tuberculosis), blood clots, liver problems, or increased risk of certain cancers. Patients are usually screened for infections before starting treatment.